Nebivolol

[1]  M. Galderisi,et al.  β-Blockers and Coronary Flow Reserve , 2012, Drugs.

[2]  D. Rizzoni,et al.  Metabolic Profile of Nebivolol, a β-Adrenoceptor Antagonist with Unique Characteristics , 2012, Drugs.

[3]  G. Lembo,et al.  Nitric oxide mechanisms of nebivolol , 2009, Therapeutic advances in cardiovascular disease.

[4]  J. Trochu,et al.  Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. , 2009, Journal of the American College of Cardiology.

[5]  J. Balligand.  beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?". , 2009, Journal of the American College of Cardiology.

[6]  G. Novo,et al.  Prognostic role of endothelial dysfunction and carotid intima-media thickness in patients undergoing coronary stent implantation. , 2009, International angiology : a journal of the International Union of Angiology.

[7]  M. Metra,et al.  Treatment of heart failure in the elderly: never say it's too late. , 2008, European heart journal.

[8]  T. Eschenhagen,et al.  β-Adrenergic stimulation and myocardial function in the failing heart , 2009, Heart Failure Reviews.

[9]  C. Mozzini,et al.  Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. , 2008, American journal of hypertension.

[10]  S. Bangalore,et al.  Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. , 2008, Journal of the American College of Cardiology.

[11]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[12]  H. M. Wright,et al.  Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. , 2008, Cardiovascular therapeutics.

[13]  L. Ignarro.  Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol. , 2008, Cardiovascular therapeutics.

[14]  Suresh Poosala,et al.  Cardioprotective and Survival Benefits of Long-Term Combined Therapy with β2 Adrenoreceptor (AR) Agonist and β1 AR Blocker in Dilated Cardiomyopathy Postmyocardial Infarction , 2008, Journal of Pharmacology and Experimental Therapeutics.

[15]  M. G. Modena,et al.  Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. , 2008, Journal of the American College of Cardiology.

[16]  Yasmin,et al.  A comparison of atenolol and nebivolol in isolated systolic hypertension , 2008, Journal of hypertension.

[17]  G. Lembo,et al.  Nebivolol Induces Nitric Oxide Release in the Heart Through Inducible Nitric Oxide Synthase Activation , 2007, Hypertension.

[18]  R. Weiss,et al.  A Randomized, Double‐Blind, Placebo‐Controlled Parallel‐Group Study to Assess the Efficacy and Safety of Nebivolol, a Novel β‐Blocker, in Patients With Mild to Moderate Hypertension , 2007 .

[19]  P. Poole‐Wilson,et al.  Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. , 2007, American heart journal.

[20]  R. Schwinger,et al.  Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum. , 2007, Life sciences.

[21]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[22]  R. Schwinger,et al.  NITRIC OXIDE, ERECTILE DYSFUNCTION AND BETA‐BLOCKER TREATMENT (MR NOED STUDY): BENEFIT OF NEBIVOLOL VERSUS METOPROLOL IN HYPERTENSIVE MEN , 2007, Clinical and experimental pharmacology & physiology.

[23]  H. Gullu,et al.  Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy , 2006, Heart.

[24]  H. Gullu,et al.  Different effects of atenolol and nebivolol on coronary flow reserve , 2006, Heart.

[25]  T. Heise,et al.  Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients , 2006, Journal of hypertension.

[26]  E. Picano,et al.  The prognostic impact of coronary flow-reserve assessed by Doppler echocardiography in non-ischaemic dilated cardiomyopathy. , 2006, European heart journal.

[27]  Ira Tabas,et al.  Letter by Williams and Tabas regarding article "atherosclerosis 2005: recent discoveries and novel hypotheses". , 2006, Circulation.

[28]  T. Cleophas,et al.  Nationwide Efficacy-Safety Study of Nebivolol in Mildly Hypertensive Patients , 2006, American journal of therapeutics.

[29]  J. Cleland,et al.  Pharmacokinetic and pharmacodynamic characteristics of beta-blockers: when differences may matter. , 2006, Journal of cardiac failure.

[30]  Alice Stanton,et al.  Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study , 2006, Circulation.

[31]  M. Yılmaz,et al.  Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients , 2006, Journal of hypertension.

[32]  S. Douma,et al.  Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. , 2006, Asian journal of andrology.

[33]  P. Poole‐Wilson,et al.  Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. , 2006, European heart journal.

[34]  S. Castro,et al.  Effects of Nebivolol versus Carvedilol on Left Ventricular Function in Patients with Chronic Heart Failure and Reduced Left Ventricular Systolic Function , 2006, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[35]  A. Wagstaff,et al.  Nebivolol: a review of its use in the management of hypertension and chronic heart failure. , 2006, Drugs.

[36]  Michael A. Weber,et al.  The Role of the New β-Blockers in Treating Cardiovascular Disease , 2005 .

[37]  L. Lindholm,et al.  Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis , 2005, The Lancet.

[38]  J. Lekakis,et al.  Effect of Nebivolol and Atenolol on Brachial Artery Flow-Mediated Vasodilation in Patients with Coronary Artery Disease , 2005, Cardiovascular Drugs and Therapy.

[39]  J. Balligand,et al.  Endothelial β3-Adrenoreceptors Mediate Nitric Oxide–Dependent Vasorelaxation of Coronary Microvessels in Response to the Third-Generation β-Blocker Nebivolol , 2005, Circulation.

[40]  C. Bulpitt,et al.  Quality of life and antihypertensive effect with nebivolol and losartan. , 2005, American Journal of Hypertension.

[41]  Z. Gąsior,et al.  Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study , 2005, European journal of heart failure.

[42]  A. Bonartsev,et al.  P-119: A new system of nitric oxide donor prolonged delivery on basis of controlled-release polymer, polyhydroxybutyrate , 2005 .

[43]  M. Bristow,et al.  P-121: Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium , 2005 .

[44]  G. Sesti,et al.  Interaction between vascular dysfunction and cardiac mass increases the risk of cardiovascular outcomes in essential hypertension. , 2005, European heart journal.

[45]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[46]  M. Zoghi,et al.  A Randomised Comparison of the Effects of Nebivolol and Atenolol with and without Chlorthalidone on the Sexual Function of Hypertensive Men , 2005, Clinical drug investigation.

[47]  T. Lüscher,et al.  Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. , 2006, Cardiovascular drug reviews.

[48]  L. Lindholm,et al.  Atenolol in hypertension: is it a wise choice? , 2004, The Lancet.

[49]  G. de Simone,et al.  Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease , 2004, Journal of hypertension.

[50]  D. Webb,et al.  Nebivolol Increases Arterial Distensibility In Vivo , 2004, Hypertension.

[51]  H. Drexler,et al.  Endothelial function: a critical determinant in atherosclerosis? , 2004, Circulation.

[52]  P. Poole‐Wilson,et al.  Beta-Blockers in Heart Failure: Are Pharmacological Differences Clinically Important? , 2004, Heart Failure Reviews.

[53]  A. Zanchetti.  Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide‐mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients , 2004, Blood pressure. Supplement.

[54]  I. Édes,et al.  Comparison of the New Cardioselective Beta-Blocker Nebivolol with Bisoprolol in Hypertension: The Nebivolol, Bisoprolol Multicenter Study (NEBIS) , 2003, Cardiovascular Drugs and Therapy.

[55]  M. Metra,et al.  β‐Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long‐term effects of atenolol vs. nebivolol , 2003, European journal of heart failure.

[56]  J. Balligand,et al.  Nitric Oxide and Cardiac Function: Ten Years After, and Continuing , 2003, Circulation research.

[57]  Otto Kamp,et al.  Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. , 2003, The American journal of cardiology.

[58]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[59]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[60]  B. Casadei,et al.  Nitric-oxide-mediated regulation of cardiac contractility and stretch responses. , 2003, Progress in biophysics and molecular biology.

[61]  G. Mancia,et al.  Efficacy and tolerability profile of nebivolol vs atenolol in mild‐to‐moderate essential hypertension: Results of a double‐blind randomized multicentre trial , 2003, Blood pressure. Supplement.

[62]  D. Rizzoni,et al.  Evaluation of the Efficacy and Tolerability of Nebivolol versus Lisinopril in the Treatment of Essential Arterial Hypertension: A Randomized, Multicentre, Double-blind Study , 2003, Blood pressure. Supplement.

[63]  T. Risler,et al.  Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study , 2002, European journal of heart failure.

[64]  P. Chowienczyk,et al.  Comparison of the Effects of Nebivolol and Bisoprolol on Systemic Vascular Resistance in Patients with Essential Hypertension , 2002 .

[65]  A. Mazza,et al.  Nebivolol vs Amlodipine as First-line Treatment of Essential Arterial Hypertension in the Elderly , 2002, Blood pressure.

[66]  R. Schwinger,et al.  Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium , 2001, British journal of pharmacology.

[67]  Y. Lacourciére,et al.  Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients , 2001, Journal of hypertension.

[68]  T. MacDonald,et al.  Nebivolol Reverses Endothelial Dysfunction in Essential Hypertension: A Randomized, Double-Blind, Crossover Study , 2001, Circulation.

[69]  M. Metra,et al.  Differential Effects of β-Blockers in Patients With Heart Failure , 2000 .

[70]  M. Metra,et al.  A rationale for the use of β-blockers as standard treatment for heart failure , 2000 .

[71]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[72]  Catherine Communal,et al.  Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein , 1999 .

[73]  B. Massie.  Clinical trials in heart failure: can we expect the results to be replicated in clinical practice? , 1998, Journal of cardiac failure.

[74]  Y. Lacourciére,et al.  Nebivolol Versus Nifedipine in the Treatment of Essential Hypertension: A Double‐Blind, Randomized, Comparative Trial , 1998, American journal of therapeutics.

[75]  L. Nueten,et al.  Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial , 1998, Journal of Human Hypertension.

[76]  L. Nueten,et al.  Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial , 1997, Journal of Human Hypertension.

[77]  R. Fogari,et al.  Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes , 1997, Journal of Human Hypertension.

[78]  M. Rousseau,et al.  Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. , 1996, Journal of cardiac failure.

[79]  J. Ritter,et al.  Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. , 1995, The Journal of pharmacology and experimental therapeutics.

[80]  M. Metra,et al.  Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.

[81]  J. Vincent,et al.  Administration of Nebivolol After Coronary Artery Bypass in Patients with Altered Left Ventricular Function , 1993, Journal of cardiovascular pharmacology.

[82]  W. Wijns,et al.  Effects of D‐Nebivolol and L‐Nebivolol on Left Ventricular Systolic and Diastolic Function: Comparison with D‐L-Nebivolol and Atenolol , 1993, Journal of Cardiovascular Pharmacology.

[83]  J. Skoularigis,et al.  Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[84]  Y. Lacourciére,et al.  Comparative Effects of a New Cardioselective Beta‐Blocker Nebivolol and Nifedipine Sustained‐Release on 24‐Hour Ambulatory Blood Pressure and Plasma Lipoproteins , 1992, Journal of clinical pharmacology.

[85]  T. Cianciulli,et al.  Effects of Nebivolol on Left Ventricular Function in Patients with Essential Hypertension , 1991 .

[86]  M. Komajda,et al.  Pilot Study of Cardiovascular Effects of Nebivolol in Congestive Heart Failure , 1991 .

[87]  U. Tebbe,et al.  Hemodynamic Effects of Nebivolol at Rest and on Exertion in Patients with Heart Failure , 1990, Angiology.

[88]  H. Verhaegen,et al.  Comparison of the Subacute Hemodynamic Effects of Atenolol, Propranolol, Pindolol, and Nebivolol , 1990, Angiology.

[89]  J. Vandevivere,et al.  Hemodynamic Effects of Nebivolol in Men: Comparison of Radionuclide Angiocardiography with Systolic Time Intervals , 1988, Angiology.

[90]  R. Reneman,et al.  Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. , 1988, Journal of cardiovascular pharmacology.